SCHEMBL1348834

SCHEMBL1348834

CC(C)(C)c1cc(/C=C/c2ccc(NS(C)(=O)=O)cc2)c(O)c(-c2ccc[nH]c2=O)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.57
TRPV1 Q8NER1 7/20 0.37
PDPK1 O15530 1/20 0.36
PIP4K2A P48426 1/20 0.34
PIP4K2B P78356 1/20 0.34
PIP4K2C Q8TBX8 1/20 0.34
PADI4 Q9UM07 1/20 0.33
HSD17B1 P14061 1/20 0.32
HSD17B2 P37059 1/20 0.32
BRD4 O60885 1/20 0.32
EP300 Q09472 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
HSP90AA1 P07900 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
IKBKB O14920 1/20 0.32
CHUK O15111 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1350078 1.00 CYP3A4 (0.57) CYP3A4TRPV1PDPK1PIP4K2APIP4K2B
SCHEMBL12849878 0.87 CYP3A4 (0.55) CYP3A4TRPV1PDPK1PIP4K2APIP4K2B
SCHEMBL1348881 0.83 CYP3A4 (0.58) CYP3A4TRPV1PDPK1PIP4K2APIP4K2B
SCHEMBL1465170 0.83 CYP3A4 (0.58) CYP3A4TRPV1PDPK1PIP4K2APIP4K2B
SCHEMBL2127415 0.82 CYP3A4 (0.62) CYP3A4TRPV1PDPK1PADI4BRD4
SCHEMBL1542584 0.82 CYP3A4 (0.62) CYP3A4TRPV1PDPK1PADI4BRD4
SCHEMBL1348189 0.80 CYP3A4 (0.57) CYP3A4TRPV1PDPK1PIP4K2APIP4K2B
SCHEMBL1349042 0.79 CYP3A4 (0.38) CYP3A4TRPV1
SCHEMBL1349044 0.79 CYP3A4 (0.38) CYP3A4TRPV1
SCHEMBL1543237 0.76 CYP3A4 (0.68) CYP3A4TRPV1PDPK1PIP4K2APIP4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063072-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-22 US claimed
US-20110070189-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS LI JIM 2011-03-24 US claimed
US-8063072-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-22 US disclosed
WO-2011033045-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-24 WO disclosed
US-20110070189-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS LI JIM 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110070189-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, HCCS, RTF2 CYP3A4 305/4885TRPV1 4388/4885PDPK1 3478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.